CTSO

SEC source: 0001104659-23-126421 · tm2332958-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,068,704

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes: (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and onethird of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 87,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 26,334 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 739,370 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-102316 · tm2326524-1_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-09-18

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options shall vest as follows: (i) 10,000 shares underlying these stock options shall vest on the date of grant, (ii) 10,000 shares underlying these stock options shall vest on the first anniversary of the date of grant, and (iii) 10,000 underlying these stock options shall vest on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-102316 · tm2326524-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 442,347

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as follows: (i) 25,000 RSUs shall vest on the date of grant, (ii) 10,000 RSUs shall vest on the first anniversary of the date of grant, and (iii) 10,000 RSUs shall vest on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") of CytoSorbents Corporation (the "Company") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: 18,500 RSUs granted on August 10, 2022; and

F4 · balance_after: (continued from footnote 3) (iii) 197,347 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-23-088977 · tm2317159-3_4.xml · nonDerivative · entry 3

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,800

F1 · balance_after: Includes (a) the following restricted stock units which will vest upon a "Change of Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, and (iii) 60,000 restricted stock units granted on June 7, 2016, and (b) 18,500 shares of common stock owned by the reporting person.

SEC source: 0001104659-23-088977 · tm2317159-3_4.xml · nonDerivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,800

F1 · balance_after: Includes (a) the following restricted stock units which will vest upon a "Change of Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, and (iii) 60,000 restricted stock units granted on June 7, 2016, and (b) 18,500 shares of common stock owned by the reporting person.

SEC source: 0001104659-23-088977 · tm2317159-3_4.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,800

F1 · balance_after: Includes (a) the following restricted stock units which will vest upon a "Change of Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, and (iii) 60,000 restricted stock units granted on June 7, 2016, and (b) 18,500 shares of common stock owned by the reporting person.

SEC source: 0001104659-23-080105 · tm2321021-7_4seq1.xml · derivative · entry 3

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2033-07-07

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080105 · tm2321021-7_4seq1.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock · 112,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080105 · tm2321021-7_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,006,548

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) the following RSUs that will be settled into shares of the Issuer's Common Stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs: (i) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and (ii) 87,000 RSUs granted on July 7, 2023 and reported on this Form 4; and

F4 · balance_after: (continued from footnote 3) (c) 650,881 shares of the Issuer's common stock owned by the reporting person.

SEC source: 0001104659-23-080106 · tm2321021-8_4seq1.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest fully on the first anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080104 · tm2321021-6_4seq1.xml · derivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-07-07

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080103 · tm2321021-5_4seq1.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080102 · tm2321021-4_4seq1.xml · derivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080101 · tm2321021-3_4seq1.xml · derivative · entry 2

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · derivative · entry 3

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-07-07

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,000

Underlying: Common Stock · 78,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,648

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) (i) 120,000 RSUs granted on April 9, 2020 that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan");

F3 · balance_after: (continued from footnote 2) (b) the following RSUs: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (these RSUs cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date); (b) 55,000 RSUs granted on August 10, 2022 and unvested on the date hereof (these RSUs vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and (c) 55,000 RSUs granted on July 7, 2023 and reported on this Form 4; and

F4 · balance_after: (continued from footnote 3) (c) 46,981 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2033-07-07

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and one-fourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 576,153

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and shall vest as to one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs: (i) 46,000 RSUs granted on August 10, 2022 and unvested as of the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and (ii) 73,000 RSUs granted on July 7, 2023 and reported on this Form 4; and

F4 · balance_after: (continued from footnote 3) (c) 250,153 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 47,000

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 45,900

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 44,800

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 43,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 40,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 38,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-042297 · tm2311913d1_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These stock options were originally granted on April 4, 2013 and became exercisable at the discretion of the Board of Directors of the Company upon the achievement of certain milestones connected to the Company's operations.

SEC source: 0001104659-23-042297 · tm2311913d1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F2 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 46,000 RSUS granted on August 10, 2021 and unvested on the date hereof ; and

F3 · balance_after: (continued from footnote 3) (c) 238,250 shares of Common Stock owned by the reporting person, inclusive of the 10,000 shares reported on this Form 4.

SEC source: 0001104659-23-042221 · tm2311822d1_4.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,500 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These stock options were originally granted on April 4, 2013 and became exercisable at the discretion of the Board of Directors of the Company upon the achievement of certain milestones connected to the Company's operations.

SEC source: 0001104659-23-042221 · tm2311822d1_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 927,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F2 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F3 · balance_after: (continued from footnote 3) (c) 635,112 shares of the Issuer's common stock owned by the reporting person, inclusive of the 30,500 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-23-027440 · tm238212-1_4seq1.xml · nonDerivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Bernard Sobel Revocable Trust

Disclosed balance after: 0

F1 · kind: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

F1 · ownership.nature: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

SEC source: 0001104659-23-027440 · tm238212-1_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,300

F1 · kind: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 restricted stock units granted on March 15, 2018, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015 and (ii) 12,000 shares of common stock owned directly by the reporting person.

SEC source: 0001104659-23-012103 · tm235846-1_4seq1.xml · derivative · entry 2

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2023-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant.

SEC source: 0001104659-23-012103 · tm235846-1_4seq1.xml · nonDerivative · entry 1

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person.

SEC source: 0001104659-22-125893 · tm2232376d1_4.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 897,279

F1 · kind: The transaction reported on this Form 4 reflects an open market purchase made by the reporting person.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 604,612 shares of the Issuer's common stock owned by the reporting person, inclusive of the 5,859 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-125503 · tm2232267-1_4seq1.xml · nonDerivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891,420

F1 · kind: The transactions reported on this Form 4 reflect open market purchases made by the reporting person.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 598,753 shares of the Issuer's common stock owned by the reporting person, inclusive of the total of 24,141 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-125503 · tm2232267-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 881,570

F1 · kind: The transactions reported on this Form 4 reflect open market purchases made by the reporting person.

SEC source: 0001104659-22-099104 · tm2225533-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 867,279

F1 · kind: The transaction reported on this Form 4 reflects an open market purchase made by the reporting person.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 574,612 shares of the Issuer's common stock owned by the reporting person, inclusive of the 35,000 shares of the Issuer's common stock reported on this Form 4.

SEC source: 0001104659-22-095149 · tm2224654-1_4.xml · nonDerivative · entry 1

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,300

F1 · shares: The transaction reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 1,000 shares of owned directly reported by the reporting person and reported on this Form 4.

SEC source: 0001104659-22-090246 · tm2223355-2_4seq1.xml · derivative · entry 3

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 60,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 60,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 60,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 60,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090246 · tm2223355-2_4seq1.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,000

Underlying: Common Stock · 106,000 shares

Expires 2032-08-10

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090246 · tm2223355-2_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 845,130

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes (a) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 79,000 RSUs granted on August 10, 2022 reported on this Form 4 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 526,130 shares of the Common Stock owned by the reporting person.

SEC source: 0001104659-22-090262 · tm2223355d10_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,975

Underlying: Common Stock · 18,975 shares

Expires 2032-08-10

F3 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090261 · tm2223355d9_4seq1.xml · derivative · entry 2

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,975

Underlying: Common Stock · 18,975 shares

Expires 2032-08-10

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090259 · tm2223355d7_4seq1.xml · derivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,975

Underlying: Common Stock · 18,975 shares

Expires 2032-08-10

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090260 · tm2223355d8_4seq1.xml · derivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,975

Underlying: Common Stock · 18,975 shares

Expires 2032-08-10

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090257 · tm2223355-6_4seq1.xml · derivative · entry 2

Kraus Al · CIK 0001368152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,950

Underlying: Common Stock · 37,950 shares

Expires 2032-08-10

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · derivative · entry 4

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 100,000 options will vest if the Company obtains one U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 50,000 options will vest if the Company obtains a second U.S. Food and Drug Administration approval for its product DrugSorb, (iii) 60,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iv) 60,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (v) 30,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · derivative · entry 3

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,000

Underlying: Common Stock · 74,000 shares

Expires 2032-08-10

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · nonDerivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,384

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes (a) (i) 120,000 RSUs granted on April 9, 2020 and (ii) 55,000 RSUs granted on August 10, 2022 and reported on this Form 4, in each case that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan";

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 13,334 RSUs granted on April 12, 2021 and unvested on the date hereof; (b) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof and (c) 52,000 RSUs granted on August 10, 2022 reported on this Form 4 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 23,050 shares of Common Stock owned by the reporting person.